Results 21 to 30 of about 49,296 (268)
Presence of cerebral microbleeds is associated with cognitive decline in acromegaly
Frontiers in Oncology, 2022 BackgroundCognitive decline in acromegaly has gained increasing attention. Cerebral microbleeds (CMBs) as radiographic markers for microvascular injury have been linked to various types of cognitive decline. However, the association between CMB formation
Zhengxing Xie +7 more
doaj +1 more source
Global epidemiology of acromegaly: a systematic review and meta-analysis.
European Journal of Endocrinology, 2021 OBJECTIVE To date, no systematic reviews and meta-analysis on the global epidemiology of acromegaly are available in literature. The aims of this study are to provide a systematic review and a meta-analysis of the global epidemiology of acromegaly and to
S. Crisafulli +13 more
semanticscholar +1 more source
مجلة بغداد للعلوم, 2023 The purpose of this study was to measure serum levels of insulin-like growth factor-binding protein (IGFBP7), Insulin-like Growth Factor 1 (IGF-1), Growth Hormone (GH), Interleukin 6 (IL-6) and insulin in acromegaly patients and healthy controls.
Layla Othman Farhan +3 more
doaj +1 more source
A Pituitary Society update to acromegaly management guidelines
Pituitary, 2020 Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes.
M. Fleseriu +10 more
semanticscholar +1 more source
Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly
Journal of Clinical Endocrinology and Metabolism, 2022 Context Diabetes is a major risk factor for cardiovascular disease and death but its effect on outcomes in acromegaly is unknown. Objective This work aimed to study whether diabetes affects morbidity and mortality in patients with acromegaly.
D. Esposito +6 more
semanticscholar +1 more source
BMJ, 2007 Growth hormone (GH) is necessary for normal linear growth. Excess secretion of GH induces gigantism in prepubertal children and acromegaly in adults. Acromegaly arises from GH-secreting pituitary adenomas. Syndromes of excessive secretion of GH or acromegaly are caused 95 % of the time by a pituitary adenoma of the somatotrophs.
openaire +4 more sources
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.
Journal of Clinical Endocrinology and Metabolism, 2020 OBJECTIVE The aim of the Acromegaly Consensus Group was to revise and update the consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013.
A. Giustina +49 more
semanticscholar +1 more source
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
European Journal of Endocrinology, 2021 Objective To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY. Design Global (15 countries), multicentre, non-interventional study (2004–2017).
M. Fleseriu +12 more
semanticscholar +1 more source
Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study
Biomedicines, 2023 Acromegaly is a rare endocrine disorder caused by somatotroph pituitary adenoma. Besides its typical symptoms, it contributes to the development of cardiovascular, metabolic, and bone comorbidities. H19 RNA is a long non-coding RNA and it is suspected to
Małgorzata Rolla +4 more
doaj +1 more source
Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea [PDF]
Endocrinology and Metabolism, 2023 Background Acromegaly leads to various skeletal complications, and fragility fractures are emerging as a new concern in patients with acromegaly. Therefore, this study investigated the risk of fractures in Korean patients with acromegaly. Methods We used
Jiwon Kim +7 more
doaj +1 more source